HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- hydroxy- N,N- dimethyl- 3- (2- ((1- (5- methylfuran- 2- yl)propyl)amino)- 3,4- dioxocyclobut- 1- enylamino)benzamide

structure in first source

Also Known As:

MK-7123; SCH 527123; SCH-527123; SCH527123

Networked: 22 relevant articles (5 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lin, Jiayuh: 2 articles (05/2022 - 07/2018)
2.	Clark, J David: 2 articles (12/2019 - 01/2017)
3.	Liang, De-Yong: 2 articles (12/2019 - 01/2017)
4.	Sahbaie, Peyman: 2 articles (12/2019 - 01/2017)
5.	Shi, Xiaoyou: 2 articles (12/2019 - 01/2017)
6.	Dale, David C: 2 articles (05/2015 - 04/2015)
7.	Rosenberg, Elizabeth: 2 articles (05/2015 - 04/2015)
8.	Stryszak, Paul: 2 articles (05/2015 - 10/2013)
9.	Khalilieh, Sauzanne: 2 articles (04/2015 - 10/2013)
10.	Sadeh, J: 2 articles (07/2012 - 03/2010)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 05/01/2015 - "Treatment with MK-7123 50 mg versus placebo led to significant improvement in FEV1 in patients with COPD, suggesting clinically important antiinflammatory effects with CXCR2 antagonism, although dose-related discontinuations were observed because of ANC decreases with MK-7123. " 05/01/2015 - "To assess the efficacy, safety, and tolerability of three dose levels of MK-7123, compared with placebo, in patients with moderate to severe COPD. " 03/01/2010 - "SCH527123 is a novel, selective CXC chemokine receptor 2 antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia, such as chronic obstructive pulmonary disease. " 05/01/2015 - "This 6-month, double-blind study randomized patients with moderate to severe COPD (already on standard therapy) to daily MK-7123 at 10, 30, or 50 mg or placebo. "
2.	Asthma (Bronchial Asthma) 07/01/2012 - "In a randomized, double-blind, parallel study, patients with severe asthma and sputum total cell count < 10 × 10(6) /g and neutrophils > 40% were randomized to SCH527123, 30 mg daily PO (n = 22) or placebo (n = 12) for 4 weeks. " 12/01/2016 - "Thirteen subjects with mild allergic asthma completed a double blind, placebo-controlled, multi-center crossover study and were randomized to daily dosing of 30 mg SCH 527123 and placebo for 8 days. " 07/01/2012 - "The SCH527123 is safe and reduces sputum neutrophils in patients with severe asthma. " 07/01/2012 - "To investigate the safety and efficacy of SCH527123, a selective CXCR2 receptor antagonist, in patients with severe asthma and increased number of neutrophils in sputum. "
3.	Ovarian Neoplasms (Ovarian Cancer) 05/01/2022 - "In the present study, the efficacy of co‑targeting IL‑6 and IL‑8 in human ovarian cancer cells by bazedoxifene (Baze) + SCH527123 (SCH) treatment was examined. "
4.	Orthomyxoviridae Infections 01/01/2021 - "SCH527123 plus oseltamivir markedly improved survival of mice infected with lethal influenza, and diminished lung pathology in swine-influenza-infected piglets. " 01/01/2021 - "Administration of a CXC Chemokine Receptor 2 (CXCR2) Antagonist, SCH527123, Together with Oseltamivir Suppresses NETosis and Protects Mice from Lethal Influenza and Piglets from Swine-Influenza Infection."
5.	Human Influenza (Influenza) 01/01/2021 - "SCH527123 plus oseltamivir markedly improved survival of mice infected with lethal influenza, and diminished lung pathology in swine-influenza-infected piglets. " 01/01/2021 - "Administration of a CXC Chemokine Receptor 2 (CXCR2) Antagonist, SCH527123, Together with Oseltamivir Suppresses NETosis and Protects Mice from Lethal Influenza and Piglets from Swine-Influenza Infection." 01/01/2021 - "Herein, temporal dynamics of neutrophil activity and NETosis were investigated to determine the optimal timing of treatment with the CXCR2 antagonist, SCH527123 (2-hydroxy-N,N-dimethyl-3-[2-([(R)-1-(5-methyl-furan-2-yl)-propyl]amino)-3,4-dioxo-cyclobut-1-enylamino]-benzamide), and its efficacy together with antiviral agent, oseltamivir, was tested in murine and piglet influenza-pneumonia models. "

Related Drugs and Biologics

1.	Interleukin-8B Receptors
2.	bazedoxifene
3.	Oseltamivir (Tamiflu)
4.	Oxaliplatin (Eloxatin)
5.	2-Hydroxypropyl-beta-cyclodextrin
6.	SCH 479833
7.	reparixin
8.	2- hydroxy- N,N- dimethyl- 3- (2- ((1- (5- methylfuran- 2- yl)propyl)amino)- 3,4- dioxocyclobut- 1- enylamino)benzamide
9.	Biphasic Insulins
10.	Fibroblast Growth Factor 7

Related Therapies and Procedures

1.	Therapeutics